EcoDrugPlus

Glutamate Receptor, Ionotropic, Ampa 1

Ensembl ID : ENSXETG00000001922
Gene Symbol: GRIA1
5 View Cross-references
322 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, Ampa 2

Ensembl ID : ENSXETG00000021375
Gene Symbol: GRIA2
9 Enzyme and pathways 4 View Cross-references
321 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, Ampa 3

Ensembl ID : ENSXETG00000019504
Gene Symbol: GRIA3
9 Enzyme and pathways 5 View Cross-references
320 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, Ampa 4

Ensembl ID : ENSXETG00000021373
Gene Symbol: GRIA4
9 Enzyme and pathways 5 View Cross-references
324 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2a

Ensembl ID : ENSXETG00000008002
Gene Symbol: GRIN2A
5 View Cross-references
227 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2b

Ensembl ID : ENSXETG00000030602
Gene Symbol: GRIN2B
13 Enzyme and pathways 5 View Cross-references
330 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2c

Ensembl ID : ENSXETG00000006844
Gene Symbol: GRIN2C
8 Enzyme and pathways 5 View Cross-references
249 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, N-Methyl D-Aspartate 2d

Ensembl ID : ENSXETG00000010593
Gene Symbol: GRIN2D
8 Enzyme and pathways 5 View Cross-references
278 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 3a

Ensembl ID : ENSXETG00000029920
Gene Symbol: GRIN3A
5 View Cross-references
245 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, N-Methyl-D-Aspartate 3b

Ensembl ID : ENSXETG00000021607
Gene Symbol: GRIN3B
5 View Cross-references
286 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, Kainate 1

Ensembl ID : ENSXETG00000011804
Gene Symbol: GRIK1
6 Enzyme and pathways 5 View Cross-references
302 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Glutamate Receptor, Ionotropic, Kainate 2

Ensembl ID : ENSXETG00000013277
Gene Symbol: GRIK2
6 Enzyme and pathways 5 View Cross-references
334 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).